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OBJECTIVE— Obesity is associated with an increased risk for cardiovascular disease (CVD).
We sought to determine rates of treatment and control of CVD risk factors among normal weight,
overweight, and obese individuals in a community-based cohort.
RESEARCH DESIGN ANDMETHODS— Participants free of CVD (n 6,801; mean
age 49 years; 54% women) from the Framingham Offspring and Third Generation cohorts who
attended the seventh Offspring examination (1998–2001) or first Third Generation (2002–
2005) examination were studied.
RESULTS— Obese participants with hypertension were more likely to receive antihyperten-
sive treatment (62.3%) than normal weight (58.7%) or overweight (59.0%) individuals (P 
0.002), but no differences in hypertension control across BMI subgroups among participants
with hypertension were observed (36.7% [normal weight], 37.3% [overweight], and 39.4%
[obese]; P 0.48). Rates of lipid-lowering treatment were higher among obese participants with
elevated LDL cholesterol (39.5%) compared with normal weight (34.2%) or overweight (36.4%)
participants (P  0.02), but control rates among those with elevated LDL cholesterol did not
differ across BMI categories (26.7% [normal weight], 26.0% [overweight], and 29.2% [obese];
P  0.11). There were no differences in diabetes treatment among participants with diabetes
across BMI groups (69.2% [normal weight], 50.0% [overweight], 55.0% [obese]; P 0.54), but
obese participants with diabetes were less likely to have fasting blood glucose 126 mg/dl
(15.7%) compared with normal weight (30.4%) or overweight (20.7%) participants (P 0.02).
CONCLUSIONS— These findings emphasize the suboptimal rates of treatment and control
of CVD risk factors among overweight and obese individuals.
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Obesity affects more than one-thirdof the adult population in the U.S.Excess weight is associated with
multiple cardiovascular disease (CVD)
risk factors, including hypertension, dys-
lipidemia, diabetes, and the metabolic
syndrome.
Although the incidence and mortality
of CVD have declined markedly during
the past decades, some studies suggested
that the increasing prevalence of obesity
and diabetes may have slowed this rate of
decline (1). In addition, recent data sug-
gest that the prevalence of chronic kidney
disease is increasing, in part because of
the increasing rates of diabetes (2). Unfor-
tunately, the efficacy of current therapies
for obesity, including lifestyle and phar-
macological interventions, is limited (3).
Although bariatric surgery is an effective
method of weight loss among severely
obese individuals, eligibility criteria limit
its use to only the most significantly af-
fected patients.
Given the current limitations of effec-
tive weight loss therapies, minimizing the
risk of complications of obesity and dia-
betes due to CVD risk factors is essential.
Few studies have focused on a compre-
hensive approach to CVD risk factor bur-
den, treatment, and control among obese
individuals. Therefore, the aim of this
study was to examine the burden of CVD
risk factors as well as rates of treatment
and control among normal weight, over-
weight, and obese individuals in an uns-
elected population-based cohort. As
abdominal fat accumulation is strongly
associated with metabolic and CVD risk
factors, and as recent guidelines have em-
phasized the importance of measuring
waist circumference as part of clinical car-
diovascular risk assessment, we also stud-
ied individuals with and without
abdominal obesity.
RESEARCH DESIGN AND
METHODS— The Framingham Heart
Study is a population-based prospective co-
hort study that commenced in 1948 and
consisted of 5,209 men and women in the
original cohort. In 1971, 5,124 men and
women were enrolled into the Framingham
Heart Study Offspring cohort, including the
children of the original cohort and their
spouses. Starting in 2002, 4,095 partici-
pants who had at least one parent in the
Offspring cohort were enrolled into the Fra-
mingham Heart Third Generation Study.
Approximately every 4 years Offspring par-
ticipants underwent examinations; the de-
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sign and methodology of the Offspring and
Third Generation cohort studies have been
previously described (4,5).
For the current study, the study sam-
ple consisted of Offspring and Third Gen-
eration participants who attended the
seventh (1998–2001) and first (2002–
2005) examination cycle, respectively. Of
7,634 participants (3,539 Offspring and
4,095 Third Generation), we excluded
those with prevalent CVD (n 463), BMI
18.5 kg/m2 or incomplete BMI data
(n 196), type 1 diabetes (n 15), miss-
ing waist circumference values (n 105),
and missing covariate data (n  54), re-
sulting in 6,801 eligible participants.
The study protocol was approved by
the institutional review boards of the Bos-
ton University Medical Center. All sub-
jects provided written informed consent.
Measurements and definitions
Height and weight were measured di-
rectly using a standardized protocol. BMI
was calculated by dividing weight in kilo-
grams by the square of the height in
meters. General obesity was defined ac-
cording to the World Health Organiza-
tion/National Institutes of Health
classification scheme. Waist circumfer-
ence was measured at the level of the um-
bilicus. Abdominal obesity was defined as
a waist circumference 88 cm (women)
and 102 cm (men).
CVD risk factor assessment
Assessment of CVD risk factors (including
fasting blood testing) was based on mea-
surements obtained during a single exam-
ination. Hypertension was defined as
systolic blood pressure of at least 140
mmHg or diastolic blood pressure of at
least 90 mmHg (based on the average of
two readings) or current use of antihyper-
tensive medication. Serum cholesterol
levels were measured in a fasting state.
Participants with elevated LDL choles-
terol levels according to their CVD risk
level as classified by the National Choles-
terol Education Program Adult Treatment
Panel III algorithm or those receiving lip-
id-lowering agents were defined as having
elevated LDL cholesterol levels. Type 2
diabetes was defined as a fasting blood
glucose level of at least 126 mg/dl (7.0
mmol/l) or current use of insulin and/or
hypoglycemic treatment for diabetes.
High-performance liquid chromatogra-
phy was used to measure H1C levels with
an assay coefficient of variation of2.5%.
Treatment and control of CVD risk
factors
To determine rates of treatment, the num-
ber of participants receiving medication
for each individual condition was divided
by the number of all participants with the
condition. Rates of control were deter-
mined by dividing the number of partici-
pants classified as having control by the
total number of individuals with the con-
dition. Control of hypertension was de-
fined as either a blood pressure of
140/90 mmHg or 130/80 mmHg for
participants with diabetes (6). Control of
LDL cholesterol levels was determined
using the participant’s specified treatment
goal according to the National Choles-
terol Education Program Adult Treatment
Panel III algorithm. Diabetes control rates
were assessed by dividing the number of
individuals with fasting blood glucose
126 mg/dl by the number of all partic-
ipants with diabetes. An A1C level of
7.0% was also used to calculate rates of
glycemic control in the Offspring cohort
only.
Statistical analysis
Prevalence and rates of treatment and
control of CVD risk factors were com-
pared among individuals in the three BMI
categories. For each risk factor, the age-
and sex-adjusted proportion of partici-
pants with the condition who were
treated and achieved control was calcu-
lated; 95% CIs were abstracted from the
logistic regression models. In all analyses,
the global P values were obtained from
models using the generalized estimation
equation (GEE) to account for familial
correlation, except for analyses for which
sample sizes were too small to permit the
GEE. In this case, ANOVA P values were
calculated. Low HDL cholesterol levels
were defined as50 mg/dl (1.29 mmol/l)
in women and 40 mg/dl (1.03 mmol/l)
in men or current use of lipid-lowering
agents. Rates of dual control of hyperten-
sion and elevated LDL C levels and triple
control of hypertension, elevated LDL
C, and fasting blood glucose were cal-
culated and compared across the three
BMI categories.
The following secondary analyses
were performed. Participants were strati-
fied by abdominal obesity. In addition,
general obesity was further categorized as
stage I (BMI 30 to35 kg/m2) and stage II
or higher (BMI 35 kg/m2) obesity; the
latter is indicated in the text simply as
stage II obesity. Participants were also
stratified by age (50 years or50 years)
and sex.
Statistical analyses were performed
using SAS statistical software (version 8;
SAS Institute, Cary, NC). Two-tailed P
0.05 and P  0.01 were considered sta-
tistically significant for primary and sec-
ondary analyses, respectively.
RESULTS— Overall, 36.1% of the
study participants (mean  SD age 49 
13 years; 54% women) were normal
weight, 38.2% were overweight, and
25.7% were obese; 47.7% had abdominal
obesity. The characteristics of the study
participants are displayed in Table 1.
Hypertension
The prevalence of hypertension increased
significantly with increasing BMI category
(P 0.001) (Table 2). Among those with
hypertension, obese participants were
more likely to be treated (62.3%) than
normal weight (58.7%) or overweight
(59.0%) participants (P  0.002). How-
ever, control rates were uniformly poor
and did not differ by BMI category (36.7%
[normal weight], 37.3% [overweight],
and 39.4% [obese]; P  0.48).
Elevated LDL cholesterol
Elevated LDL cholesterol increased with
increasing BMI categories (P  0.001)
(Table 2). Obese participants with ele-
vated LDL cholesterol were more likely to
be treated with lipid-lowering agents
(39.5%) than normal weight (34.2%) or
overweight (36.4%) participants (P 
0.02). LDL cholesterol was controlled in
less than one-third of the participants,
and rates of control did not differ by BMI
category (P  0.11).
Type 2 diabetes
Despite higher prevalence rates of diabe-
tes with increasing BMI (P  0.001) (Ta-
ble 2), there were no differences in
hypoglycemic treatment (69.2% [normal
weight], 50.0% [overweight], and 55.0%
[obese]; P 0.54) or in the prevalence of
optimal H1C levels across BMI categories
in the Offspring cohort (50.0% [normal
weight], 58.8% [overweight], and 47.7%
[obese]; P  0.26) among participants
with diabetes. Obese participants were
less likely to have fasting blood glucose
126 mg/dl (15.7%) than normal weight
(30.4%) or overweight (20.7%) partici-
pants (P  0.02).
Cardiovascular disease risk factors in obesity
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Combinations of risk factors
The number of CVD risk factors among
BMI categories is displayed in Fig. 1 of the
online appendix (available at http://
dx.doi.org/10.2337/dc07-2413); only
6.0% of obese participants had no CVD
risk factors. Dual control of hypertension
and elevated LDL cholesterol was uni-
formly low and did not differ by BMI cat-
egory (19.1% [95% CI 12.6 –27.0,
normal weight], 12.1% [9.0–15.8, over-
weight], and 16.0% [12.7–19.8, obese];
P  0.94). Rates of triple control of hy-
pertension, LDL cholesterol, and diabetes
were low and showed no differences by
BMI category (P 0.15): none of the nor-
mal weight participants with hyperten-
sion, elevated LDL cholesterol, and
diabetes (n 17) achieved optimal triple
control (0% [0–0]), and only 3 of 52
overweight participants (5.9% [1.2–
16.2]) and 2 of 131 obese individuals
achieved optimal triple control (1.6%
[0.2–5.5]).
Secondary analyses
When results were stratified by abdomi-
nal obesity, findings were not materially
different (Table 1 of the online appendix).
In analyses stratified by age, among older
participants, obese individuals with hyper-
tension were more likely to receive antihy-
pertensive treatment (74.1%) than those
with normal weight (67.4%) and over-
weight (67.5%) (P 0.006) (Table 2 of the
online appendix), whereas hypertension
treatment rates among participants 50
years were uniformly lower and similar
across BMI categories (P  0.26). Age-
stratified analyses of hypoglycemic treat-
ment demonstrated that in participants
aged50 years, obese individuals with di-
abetes were less likely to receive treatment
(39.3%) than overweight individuals with
diabetes (50.0%) (P  0.006) (Table 2 of
the online appendix).
In sex-specific analyses, obese men
were more likely to receive antihyperten-
sive treatment (56.9%) than normal
weight men (50.9%) or overweight men
(53.5%) (P  0.006) (Table 3 of the on-
line appendix), whereas treatment rates
among women were uniformly the same
across BMI categories (P  0.15). A sim-
Table 1—Characteristics of study participants within different BMI categories
BMI 18.5 to 25 kg/m2 BMI 25 to 30 kg/m2 BMI 30 kg/m2 P value*
n 2,458 2,596 1,747
Age (years) 46  14 50  13 51  13 0.001
Sex (% female) 1727 (70.3) 1093 (42.1) 866 (49.6) 0.001
Systolic blood pressure (mmHg) 115  16 122  16 127  16 0.001
Diastolic blood pressure (mmHg) 71  9 76  9 79  9 0.001
Fasting blood glucose (mg/dl) 91  12 98  17 107  29 0.001
Total cholesterol (mg/dl) 187  34 199  37 198  35 0.001
LDL cholesterol (mg/dl) 107  31 122  32 120  31 0.001
HDL cholesterol (mg/dl) 61  17 52  15 48  14 0.001
Triglycerides, median (25/75 percentiles) (mg/dl) 78 (58/109) 109 (76/161) 131 (93/184) 0.001
BMI (kg/m2) 22.5  1.6 27.3  1.4 34.6  4.5 0.001
Waist circumference (cm) 82.6  7.6 96.6  7.2 113.7  12.0 0.001
Current smoker (%) 407 (16.6) 386 (14.9) 247 (14.1) 0.14
Data are means  SD for continuous variables and n (%) for dichotomous variables. SI conversion factors: to convert glucose to millimoles per liter, multiply
milligrams per deciliter values by 0.0555; to convert total, LDL, and HDL cholesterol to millimoles per liter, multiply milligrams per deciliter values by 0.0259; and
to convert triglycerides to millimoles per liter, multiply milligrams per deciliter values by 0.0113. *Global GEE age- and sex-adjusted P value, except for age, which
is sex adjusted, and sex, which is age adjusted.
Table 2—Age-and sex-adjusted rates of hypertension, elevated levels of LDL, and type 2 diabetes, as well as treatment and control, among BMI
categories
BMI 18.5 to 25 kg/m2 BMI 25 to 30 kg/m2 BMI 30 kg/m2 P value*
n 2,458 2,596 1,747
Hypertension
Prevalence 11.5 (10.2–12.9) 22.8 (21.0–24.8) 37.6 (34.5–40.7) 0.001
Treatment 58.7 (49.8–67.1) 59.0 (52.8–65.0) 62.3 (56.1–68.2) 0.002
Control 36.7 (30.3–43.5) 37.3 (32.7–41.9) 39.4 (34.9–44.0) 0.48
Elevated LDL cholesterol levels
Prevalence 12.7 (11.3–14.2) 28.2 (26.2–30.4) 35.1 (32.2–38.2) 0.001
Treatment 34.2 (28.2–40.6) 36.4 (32.3–40.6) 39.5 (34.9–44.4) 0.02
Control 26.7 (21.5–32.4) 26.0 (22.6–29.7) 29.2 (25.3–33.4) 0.11
Diabetes
Prevalence 1.4 (0.9–1.9) 4.1 (3.4–5.0) 11.9 (10.3–13.6) 0.001
Treatment 69.2 (38.6–90.9) 50.0 (35.2–64.8) 55.0 (44.7–65.0) 0.54
A1C 7.0%† 50.0 (18.7–81.3) 58.8 (40.7–75.4) 47.7 (35.3–59.4) 0.26
Fasting plasma glucose 126 mg/dl 30.4 (13.2–52.9) 20.7 (12.8–30.7) 15.7 (10.8–21.7) 0.02
Data are % of participants (95% CI). SI conversion factor: To convert fasting plasma glucose to millimoles per liter, multiply milligrams per deciliter values by 0.0555.
*Global GEE P value. †Data available for Offspring cohort only.
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ilar pattern of sex differences was ob-
served for lipid-lowering treatment and
control of elevated LDL cholesterol (Table
3 of the online appendix). Sex-specific
analyses of elevated glucose control dem-
onstrated that among women, obese indi-
viduals with diabetes were less likely to
have fasting blood glucose 126 mg/dl
(12.8%) than normal weight (30.8%) or
overweight (32.3%) individuals (P 
0.001) (Table 3 of the online appendix),
whereas the rates among men were uni-
formly the same across BMI categories.
When the obesity category was fur-
ther broken down into stage I versus stage
II obesity, no difference in treatment or
control of hypertension (Fig. 1A), ele-
vated LDL cholesterol (Fig. 1B), or diabe-
tes (Fig. 1C) was observed despite a
higher prevalence of hypertension and di-
abetes among participants with stage II
obesity.
CONCLUSIONS
Principal findings
Despite the higher burden of CVD risk
factors among participants with obesity
from the Framingham Heart Study, rates
of treatment and control of CVD risk fac-
tors are suboptimal among overweight
and obese individuals. Among partici-
pants with obesity, only one in four with
hypertension achieved recommended
blood pressure levels, less than one-third
with elevated LDL cholesterol had opti-
mal control of these values, and only one
in six participants with diabetes achieved
fasting blood glucose 126 mg/dl. Dual
and triple controls of CVD risk factors
were uniformly poor across all BMI
categories.
Hypertension
High blood pressure is associated with an
increased risk of mortality and morbidity
from stroke, coronary heart disease, and
congestive heart failure (7) and is more
frequent in obese individuals than in lean
individuals (8). Obese participants were
more likely to receive antihypertensive
treatment but were not more likely to
achieve control. Overall, potential rea-
sons for poor blood pressure control may
include unrecognized hypertension, poor
adherence to a medication regimen (9),
and failure to initiate or intensify therapy
when indicated (10). In addition, the
pathophysiology of obesity-related hy-
pertension may differ from that of hyper-
tension among nonobese individuals
because of the presence of excess adipose
tissue. Potential mechanisms that link ad-
ipose tissue to hypertension include alter-
ations in the renin-angiotensin system,
activation of the sympathetic nervous sys-
tem, insulin resistance, sodium and vol-
ume retention, and renal dysfunction
(11). These mechanisms may have impor-
tant implications for the effectiveness of
antihypertensive therapy in obese indi-
viduals. Clinical trial data have shown
that -blockers alone (12) or in combina-
tion with doxazosin (13) more effectively
lower blood pressure in obese than in lean
hypertensive individuals. Clinical trials
have consistently shown that ACE inhib-
itors and angiotensin receptor blockers
are associated with reductions in the risk
of new-onset type 2 diabetes (14), and
there is growing evidence that drugs
blocking the renin-angiotensin system
may be beneficial in the management of
hypertension in obese individuals (15).
Current treatment guidelines do not pro-
Figure 1—Prevalence and rates of treatment and control of hypertension (A), elevated levels of
LDL cholesterol (B), and type 2 diabetes (C) among normal weight, overweight, stage I obese, and
stage II obese participants. GEE P values represent stage I obesity versus stage II obesity adjusted
for age and sex. *P  0.001.
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vide specific recommendations for obese
individuals regarding blood pressure tar-
gets and a particular treatment. This may
be due to lack of randomized clinical trials
that have focused specifically on this
question.
Elevated LDL cholesterol
Obese participants with elevated LDL
cholesterol were more likely to receive
lipid-lowering therapy, but rates of con-
trol of LDL cholesterol among affected in-
dividuals did not differ across BMI
categories. Among all participants with el-
evated LDL cholesterol, levels were well
controlled in less than one-third.
High levels of LDL cholesterol are an
important modifiable risk factor in the de-
velopment of CVD. Many primary and
secondary prevention trials have demon-
strated the efficacy and safety of statins in
reducing CVD risk. Therefore, it is sur-
prising that LDL control was so poor
among obese participants. There are sev-
eral potential reasons for this result. The
current National Cholesterol Education
Program guidelines do not specifically
target obesity as a high-risk condition
warranting lower LDL targets for lipid
lowering. In addition, few clinical trials
have studied the efficacy of statins on in-
termediate markers of CVD in BMI sub-
groups to demonstrate increased benefit
among obese individuals compared with
nonobese individuals or consistent effects
across subgroups. Lastly, clinical trials
studying the efficacy of statins on cardio-
vascular outcomes in BMI subgroups are
lacking.
Type 2 diabetes
The prevalence of diabetes has increased
substantially over the last several decades
(16), likely due to increases in obesity,
and the prevalence of obesity among in-
dividuals with diabetes increased by 50%
between 1970 and 1989 (17). Rates of
CVD associated with type 2 diabetes are
high (18), and recent increases in chronic
kidney disease may be due in part to in-
creases in obesity and diabetes (2).
Despite this, we observed similarly
low rates of treatment and control of A1C
levels across BMI subgroups. There may
be several potential reasons for the ob-
served poor glycemic control. First, dia-
betes may be unrecognized and therefore
untreated. Second, clinical trial data dem-
onstrating CVD event reduction in the
setting of optimal glycemic control is
lacking. However, improved blood glu-
cose control reduces the risk of chronic
kidney disease and diabetic retinopathy
(19). Third, patients may not be comply-
ing with treatment regimens, including
diet and exercise recommendations. Un-
desirable side effects due to antidiabetic
agents, in particular weight gain in the
setting of insulin treatment, may limit
treatment adherence as well. Last, clinical
trials suggest that diabetes is more diffi-
cult to control among obese individuals
(20).
We have shown that material differ-
ences in treatment of diabetes do not exist
across BMI categories and that obese in-
dividuals are less likely to achieve optimal
fasting blood glucose levels. The majority
of diabetes occurs in obese individuals.
Our results highlight the vast numbers of
cases of untreated and uncontrolled dia-
betes in this subgroup.
Control of combinations of risk
factors
Rates of dual and triple control of CVD
risk factors were uniformly poor across
BMI categories in our study sample. Clus-
tering of metabolic abnormalities contrib-
utes cumulatively to CVD risk and
complicates treatment (21). These data
emphasize the importance of a treatment
regimen aimed to control multiple risk
factors.
Clinical implications and future
research
The suboptimal rates of diabetes treat-
ment and control of CVD risk factors in
obese participants in the current study are
of particular concern, given the increasing
rates of overweight and obesity among
U.S. adults. Without substantial improve-
ments in CVD risk factor treatment and
control rates among obese individuals,
the medical and financial burden of CVD
events may grow substantially in the next
several decades. There is a paucity of clin-
ical trial data specifically testing interven-
tions in obese subgroups to determine
whether more intensive risk factor man-
agement or obesity-specific treatment and
control guidelines would result in de-
creased CVD outcomes. Additionally,
there is a need for more effective pharma-
cotherapy for obesity.
Strengths and limitations
Strengths of our study include the exam-
ination of a large, population-based sam-
ple of women and men with a broad age
spectrum and standardized assessment of
anthropometric measures and CVD risk
factors and treatment. Several limitations
should be acknowledged. We used guide-
lines for treatment that were not necessar-
ily in place at the time of data collection.
However, the aim of current study was to
characterize the burden of CVD risk fac-
tors using the most contemporary data
available. The data collection period
spanned from 1998 to 2005, and rates of
treatment or control of CVD risk factors
may have changed during this period.
Participants in the Offspring cohort were
followed for several years and may have
benefited with respect to risk factor re-
duction, as the findings of each examina-
tion were reviewed and letters were sent
to the physician. However, our rates of
treatment and control of CVD risk factors
are similar to data from national surveys
(22), suggesting that the rates of treat-
ment and control mirror national data.
Further, the data in the present study
from the Third Generation cohort repre-
sent their first examination, minimizing
this concern. The Framingham Heart
Study Offspring and Third Generation
cohort participants are primarily white;
therefore the generalizability of our find-
ings to other racial groups may be limited.
Lastly, we did not examine the reasons for
low rates of treatment and control.
In summary, rates of treatment and
control of CVD risk factors are subopti-
mal among overweight and obese individ-
uals in the Framingham Heart Study.
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